中東呼吸器症候群(MERS)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0526
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2019, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Middle East Respiratory Syndrome (MERS) – Overview
Middle East Respiratory Syndrome (MERS) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Middle East Respiratory Syndrome (MERS) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Middle East Respiratory Syndrome (MERS) – Companies Involved in Therapeutics Development
Abhelix LLC
Anglo Biopharma Ltd
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Future Medicine Co Ltd
Gilead Sciences Inc
Global BioLife Inc Ltd
Greffex Inc
Humabs BioMed SA
Inovio Pharmaceuticals Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laboratories LC
SAB Biotherapeutics Inc
Signia Therapeutics
Sumagen Co Ltd
Themis Bioscience GmbH
Vaccitech Ltd
Middle East Respiratory Syndrome (MERS) – Drug Profiles
Middle East Respiratory Syndrome (MERS) – Dormant Projects
Middle East Respiratory Syndrome (MERS) – Discontinued Products
Middle East Respiratory Syndrome (MERS) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Abhelix LLC, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Anglo Biopharma Ltd, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Future Medicine Co Ltd, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Global BioLife Inc Ltd, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Greffex Inc, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by SAB Biotherapeutics Inc, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Signia Therapeutics, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Sumagen Co Ltd, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Themis Bioscience GmbH, H2 2019
Middle East Respiratory Syndrome (MERS) - Pipeline by Vaccitech Ltd, H2 2019
Middle East Respiratory Syndrome (MERS) - Dormant Projects, H2 2019

【掲載企業】

Abhelix LLC
Anglo Biopharma Ltd
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Future Medicine Co Ltd
Gilead Sciences Inc
Global BioLife Inc Ltd
Greffex Inc
Humabs BioMed SA
Inovio Pharmaceuticals Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laboratories LC
SAB Biotherapeutics Inc
Signia Therapeutics
Sumagen Co Ltd
Themis Bioscience GmbH
Vaccitech Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[中東呼吸器症候群(MERS)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆